1
|
Zhu J, Zhang H, Lan H, Bi B, Peng X, Li D, Wang H, Zhu K, Shao F, Yin M. Enhancing breast cancer treatment: mesoporous dopamine nanoparticles in synergy with chrysin for photothermal therapy. Front Oncol 2024; 14:1427858. [PMID: 39045563 PMCID: PMC11263883 DOI: 10.3389/fonc.2024.1427858] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2024] [Accepted: 06/19/2024] [Indexed: 07/25/2024] Open
Abstract
Introduction Breast cancer is one of the most prevalent cancers, primarily affecting women. Among its subtypes, estrogen receptor-positive (ER+) breast cancer is particularly common. Inhibiting estrogen's effects is crucial for treating ER+ breast cancer, but current therapies often have significant side effects and limitations. Chrysin, a natural flavonoid, has shown potential in reducing estrogen receptor expression, but its poor water solubility hampers clinical application. This study explores the use of mesoporous dopamine nanoparticles (mPDA) to enhance the delivery and efficacy of Chrysin, combined with photothermal therapy (PTT), for breast cancer treatment. Methods Chrysin-loaded mPDA nanoparticles (Chrysin@mPDA) were synthesized and characterized for their morphology, drug-loading efficiency, stability, and photothermal properties. Network pharmacology was used to predict Chrysin's mechanisms in breast cancer, which were validated through gene expression analysis in cell experiments. The therapeutic efficacy of Chrysin@mPDA with and without PTT was evaluated in a mouse model of breast cancer, with tumor volume and weight measured. Immunohistochemical analysis was conducted to assess estrogen receptor expression and immune cell infiltration in tumor tissues. Results Chrysin@mPDA nanoparticles demonstrated a high drug-loading capacity and excellent stability. Photothermal studies confirmed the nanoparticles' ability to generate heat upon laser exposure, significantly enhancing Chrysin release in acidic conditions with laser irradiation. Network pharmacology identified key target genes affected by Chrysin, including ESR1, BRCA1, CTNNB1, and BAX, which were validated through qPCR. In vivo, the combination of Chrysin@mPDA and PTT significantly reduced tumor volume and weight, decreased estrogen receptor-positive cells, and increased infiltration of CD3+CD4+ and CD3+CD8+ T cells in tumor tissues. Discussion The study highlights the potential of Chrysin-loaded mPDA nanoparticles combined with PTT as an effective strategy for breast cancer treatment. This approach addresses the limitations of Chrysin's solubility and enhances its therapeutic efficacy through synergistic mechanisms. The dual action of Chrysin in modulating gene expression and PTT in inducing localized hyperthermia and immune response suggests a promising avenue for improved breast cancer prognosis and reduced recurrence.
Collapse
Affiliation(s)
- Jing Zhu
- Health Management Center, Zigong First People’s Hospital, Zigong, China
| | - Heng Zhang
- Medical Imaging Center, Dazhou Central Hospital, Dazhou, China
- Center for Precision Health, School of Medical and Health Science, Edith Cowan University, Perth, WA, Australia
| | - Haomiao Lan
- Department of Thyroid and Breast Surgery, Zigong First People’s Hospital, Zigong, China
| | - Bing Bi
- Health Management Center, Zigong First People’s Hospital, Zigong, China
| | - Xianfeng Peng
- Department of Nuclear Medicine, Zigong First People’s Hospital, Zigong, China
| | - Dandan Li
- Department of Nuclear Medicine, Zigong First People’s Hospital, Zigong, China
| | - Haili Wang
- Department of Nuclear Medicine, Zigong First People’s Hospital, Zigong, China
| | - Ke Zhu
- Department of Nuclear Medicine, Zigong First People’s Hospital, Zigong, China
| | - Fuqiang Shao
- Department of Nuclear Medicine, Zigong First People’s Hospital, Zigong, China
| | - Minggang Yin
- Department of Clinical Laboratory, Zigong First People’s Hospital, Zigong, China
| |
Collapse
|
2
|
Wang K, Zhu K, Zhu Z, Shao F, Qian R, Wang C, Dong H, Li Y, Gao Z, Zhao J. Triptolide with hepatotoxicity and nephrotoxicity used in local delivery treatment of myocardial infarction by thermosensitive hydrogel. J Nanobiotechnology 2023; 21:227. [PMID: 37461079 DOI: 10.1186/s12951-023-01980-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2023] [Accepted: 07/03/2023] [Indexed: 07/20/2023] Open
Abstract
Myocardial infarction (MI) resulting from coronary artery occlusion is the leading global cause of cardiovascular disability and mortality. Anti-inflammatory treatment plays an important role in MI treatment. Triptolide (TPL), as a Chinese medicine monomer, has a variety of biological functions, including anti-inflammatory, anti-tumor, and immunoregulation. However, it has been proved that TPL is poorly water soluble, and has clear hepatotoxicity and nephrotoxicity, which seriously limits its clinical application. Herein, we designed a long-acting hydrogel platform (TPL@PLGA@F127) for MI treatment by intramyocardial injection. First, we found that the inflammatory response and immune regulation might be the main mechanisms of TPL against MI by network pharmacology. Subsequently, we prepared the hydrogel platform (TPL@PLGA@F127) and tested its effects and toxicity on normal organs in the early stage of MI (3 days after MI-operation). The results showed that TPL@PLGA@F127 could not only promote "repair" macrophages polarization (to M2 macrophage) by day 3 after MI, but also has a long-lasting anti-inflammatory effect in the later stage of MI (28 days after MI-operation). Additionally, we proved that TPL@PLGA@F127 could attenuate the toxicity of TPL by releasing it more slowly and stably. Finally, we observed the long-term effects of TPL@PLGA@F127 on MI and found that it could improve cardiac function, depress the myocardial fibrosis and protect the cardiomyocytes. In summary, this study indicated that TPL@PLGA@F127 could not only enhance the therapeutic effects of TPL on MI, but also attenuate the hepatotoxicity and nephrotoxicity, which established a strong foundation for the clinical application of TPL for MI.
Collapse
Affiliation(s)
- Kun Wang
- Department of Nuclear Medicine, Shanghai East Hospital, School of medicine, Tongji University, Shanghai, 200120, China
- Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Hubei Key Laboratory of Molecular Imaging, Huazhong University of Science and Technology, Wuhan, 430022, Hubei, China
| | - Ke Zhu
- Department of Nuclear Medicine, The First People's Hospital of Zigong, Zigong, 643099, Sichuan, China
| | - Ziyang Zhu
- Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Hubei Key Laboratory of Molecular Imaging, Huazhong University of Science and Technology, Wuhan, 430022, Hubei, China
| | - Fuqiang Shao
- Department of Nuclear Medicine, The First People's Hospital of Zigong, Zigong, 643099, Sichuan, China
| | - Ruijie Qian
- Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China
| | - Chenyang Wang
- Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Hubei Key Laboratory of Molecular Imaging, Huazhong University of Science and Technology, Wuhan, 430022, Hubei, China
| | - Haiqing Dong
- The Institute for Biomedical Engineering & Nano Science, School of Medicine, Tongji University, Shanghai, 200092, China
| | - Yongyong Li
- The Institute for Biomedical Engineering & Nano Science, School of Medicine, Tongji University, Shanghai, 200092, China
| | - Zairong Gao
- Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Hubei Key Laboratory of Molecular Imaging, Huazhong University of Science and Technology, Wuhan, 430022, Hubei, China.
| | - Jun Zhao
- Department of Nuclear Medicine, Shanghai East Hospital, School of medicine, Tongji University, Shanghai, 200120, China.
| |
Collapse
|
3
|
Zhu K, Yao Y, Wang K, Shao F, Zhu Z, Song Y, Zhou Z, Jiang D, Lan X, Qin C. Berberin sustained-release nanoparticles were enriched in infarcted rat myocardium and resolved inflammation. J Nanobiotechnology 2023; 21:33. [PMID: 36709291 PMCID: PMC9883926 DOI: 10.1186/s12951-023-01790-w] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2022] [Accepted: 01/20/2023] [Indexed: 01/29/2023] Open
Abstract
Inflammatory regulation induced by macrophage polarization is essential for cardiac repair after myocardial infarction (MI). Berberin (BBR) is an isoquinoline tetrasystemic alkaloid extracted from plants. This study analyzes the most likely mechanism of BBR in MI treatment determined via network pharmacology, showing that BBR acts mainly through inflammatory responses. Because platelets (PLTs) can be enriched in the infarcted myocardium, PLT membrane-coated polylactic-co-glycolic acid (PLGA) nanoparticles (BBR@PLGA@PLT NPs) are used, which show enrichment in the infarcted myocardium to deliver BBR sustainably. Compared with PLGA nanoparticles, BBR@PLGA@PLT NPs are more enriched in the infarcted myocardium and exhibit less uptake in the liver. On day three after MI, BBR@PLGA@PLT NPs administration significantly increases the number of repaired macrophages and decreases the number of inflammatory macrophages and apoptotic cells in infarcted rat myocardium. On the 28th day after MI, the BBR@PLGA@PLT group exhibits a protective effect on cardiac function, reduced cardiac collagen deposition, improved scar tissue stiffness, and an excellent angiogenesis effect. In addition, BBR@PLGA@PLT group has no significant impact on major organs either histologically or enzymologically. In summary, the therapeutic effect of BBR@PLGA@PLT NPs on MI is presented in detail from the perspective of the resolution of inflammation, and a new solution for MI treatment is proposed.
Collapse
Affiliation(s)
- Ke Zhu
- grid.33199.310000 0004 0368 7223Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan, 430022 Hubei China ,grid.412839.50000 0004 1771 3250Hubei Key Laboratory of Molecular Imaging, Wuhan, 430022 Hubei China ,Department of Nuclear Medicine, The First People’s Hospital of Zigong, Zigong, Sichuan China
| | - Yu Yao
- grid.33199.310000 0004 0368 7223Department of Ultrasound, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei China
| | - Kun Wang
- grid.33199.310000 0004 0368 7223Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan, 430022 Hubei China ,grid.24516.340000000123704535Department of Nuclear Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China
| | - Fuqiang Shao
- Department of Nuclear Medicine, The First People’s Hospital of Zigong, Zigong, Sichuan China
| | - Ziyang Zhu
- grid.33199.310000 0004 0368 7223Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan, 430022 Hubei China ,grid.412839.50000 0004 1771 3250Hubei Key Laboratory of Molecular Imaging, Wuhan, 430022 Hubei China
| | - Yangmeihui Song
- grid.33199.310000 0004 0368 7223Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan, 430022 Hubei China ,grid.412839.50000 0004 1771 3250Hubei Key Laboratory of Molecular Imaging, Wuhan, 430022 Hubei China
| | - Zhangyongxue Zhou
- grid.33199.310000 0004 0368 7223Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan, 430022 Hubei China ,grid.412839.50000 0004 1771 3250Hubei Key Laboratory of Molecular Imaging, Wuhan, 430022 Hubei China
| | - Dawei Jiang
- grid.33199.310000 0004 0368 7223Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan, 430022 Hubei China ,grid.412839.50000 0004 1771 3250Hubei Key Laboratory of Molecular Imaging, Wuhan, 430022 Hubei China ,grid.419897.a0000 0004 0369 313XKey Laboratory of Biological Targeted Therapy, The Ministry of Education, Wuhan, 430022 Hubei China
| | - Xiaoli Lan
- grid.33199.310000 0004 0368 7223Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan, 430022 Hubei China ,grid.412839.50000 0004 1771 3250Hubei Key Laboratory of Molecular Imaging, Wuhan, 430022 Hubei China ,grid.419897.a0000 0004 0369 313XKey Laboratory of Biological Targeted Therapy, The Ministry of Education, Wuhan, 430022 Hubei China
| | - Chunxia Qin
- grid.33199.310000 0004 0368 7223Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan, 430022 Hubei China ,grid.412839.50000 0004 1771 3250Hubei Key Laboratory of Molecular Imaging, Wuhan, 430022 Hubei China ,grid.419897.a0000 0004 0369 313XKey Laboratory of Biological Targeted Therapy, The Ministry of Education, Wuhan, 430022 Hubei China
| |
Collapse
|